Alternatives to Samplix

Clinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.

Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.

Biopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Developing Quantum ADCs against the tumor microenvironment for innovative cancer therapies.

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

AI-driven biotechnology company developing novel protein therapeutics through generative biology.

Biotechnology company focused on cellular rejuvenation to reverse disease and extend healthspan.

Global biopharmaceutical company pioneering mRNA-based immunotherapies and vaccines for cancer and infectious diseases.

Biotechnology company leveraging ultracompact CRISPR systems for gene editing therapies and diagnostics.

Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).

Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.

A life sciences company that has developed a high-throughput platform for mapping molecular cell architecture at nanoscale resolution.

Freenome is a biotechnology company developing a multi-cancer early detection blood test using machine learning and biology.

Spatial multiomics company developing technologies for single-cell gene expression profiling in intact tissues.

Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.

Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

A vertically-integrated procurement platform for the life sciences industry.

Leveraging AI and a massive patient tissue dataset to accelerate drug discovery and advance precision medicine.

Personalizing cancer care through a novel, physics-informed approach to predict tumor response to therapy.